Mayo Clinic Phoenix

Futó vizsgálatok

• Toboroz

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· 3. fázis· Forrás

• Toboroz

  Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

  NCT07069738· Forrás

• Toboroz

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· 3. fázis· Forrás

• Toboroz

  A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

  NCT06720987· 1. fázis· Forrás

• Fut, nem toboroz

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· 3. fázis· Forrás

• Toboroz

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· 3. fázis· Forrás

• Toboroz

  Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  NCT06056830· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

  NCT06005740· 1. fázis· Forrás

• Toboroz

  A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  NCT05735184· 1. fázis· Forrás

• Fut, nem toboroz

  Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

  NCT05683691· Forrás

• Toboroz

  PROMs After Pancreatectomy

  NCT07173257· Forrás

• Toboroz

  Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

  NCT03860883· Forrás

• Toboroz

  Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

  NCT03435796· 2/3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Akut mieloid leukémia (AML)1 toboroz
• Gyermekkori daganatok1 toboroz
• Hasnyálmirigyrák1 toboroz
• Krónikus limfoid leukémia (CLL)1 toboroz
• Melanóma1 toboroz
• Mielóma multiplex1 toboroz
• Mieloproliferatív neopláziák1 toboroz
• Prosztatarák1 toboroz
• Szarkóma1 toboroz
• Szívelégtelenség1 toboroz
• Tüdőrák1 toboroz
• Vastagbélrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Toboroz

  Strategy for Improving Stroke Treatment Response

  NCT05948566· 2. fázis· Forrás

• Toboroz

  A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  NCT05006716· 1/2. fázis· Forrás

• Lezárult

  A Trial Evaluating TG4050 in Ovarian Carcinoma.

  NCT03839524· 1. fázis· Forrás

• Lezárult

  Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

  NCT02831959· 3. fázis· Forrás